Global FMS-like Tyrosine Kinase 3 Inhibitors Market

Report ID : 1389 | Published : 2022-10-07 | Pages: | Format: PDF/EXCEL

The market size of the global FMS-like tyrosine kinase 3 inhibitors market in the year 2021 is valued at 398.54 million and is predicted to reach 1253.38 million by the year 2030 at an 13.89% CAGR during the forecast period.

The effects of inhibitors have been documented in acute myeloid leukemia patients with FMS-like tyrosine kinase 3 inhibitors3 mutations, as part of the Non-Insured Health Benefits (NIHB) program. FMS-like tyrosine kinase 3 inhibitors3 is a viable molecular target in a subgroup of acute myeloid leukemia cases. The accessibility of drugs with potency and low toxicity, as well as oral forms, is spurring demand for FMS-like tyrosine kinase 3 inhibitors3 inhibitors, particularly among elderly and frail patients. One of the key reasons impacting the rise of the billion US dollars is the rising spending on Research & Development (R&D) activities by various major pharmaceutical companies. Regulatory bodies are rapidly authorizing novel FMS-like tyrosine kinase 3 inhibitors3 inhibitor treatments, the prevalence of acute myeloid leukemia and relapse patients is rising, and there are more potential medicines in production, all of which are boosting the market's revenue and profit.

The players in the global FMS-like the tyrosine kinase 3 inhibitors market, can expect lucrative revenue growth opportunities due to rising R&D activities, government initiatives to use sustainable components in production, and investments from well-known companies.

Market Segmentation:

The FMS-like tyrosine kinase 3 inhibitors market is segmented based on product and therapy outlook. Based on the therapy outlook, the market is segmented as type 1 FMS-like tyrosine kinase 3 inhibitors and type 2 FMS-like tyrosine kinase 3 inhibitors3 inhibitors. By drug type outlook, the market is segmented into Mideastern, Gilbertian and Sorafenib.

Based on therapies outlook, the type 1 FMS-like tyrosine kinase 3 inhibitors segment is accounted as a major contributor in the FMS-like tyrosine kinase 3 inhibitors market

The type 1 FMS-like tyrosine kinase 3 category is expected to hold a major share in the global FMS, like the tyrosine kinase 3 inhibitors market, in 2021 due to increased productive research and clinical trials. In acute myeloid leukemia cells with either ITD or TKD mutations, Type 1 inhibitors are more efficient because they prevent ATP binding as opposed to Type 2 FMS-LIKE TYROSINE KINASE 3 INHIBITORS3 inhibitors. Additionally, Type 1 FMS-like tyrosine kinase 3 inhibitors3 inhibitors are effective in treating patients who have relapsed due to acquired TKD mutations, which is one of the major drivers fueling the market's expansion in terms of revenue. Mideastern, crenolanib, and glitterati are examples of type 1 inhibitors. This segment's income is also growing because of medications' improved efficacy, decreased side effects, and low cytotoxicity.

Gilbertian segment witnessed growth at a rapid rate

The gilteritinib segment is projected to grow rapidly in the global FMS-like the tyrosine kinase 3 inhibitors market. As a result of ongoing clinical trials and rising regulatory approvals, acute myeloid leukemia patients with FMS-like tyrosine kinase 3 INHIBITORS3-TKD or FMS-LIKE TYROSINE KINASE 3 INHIBITORS3-ITD mutations who have relapsed or become resistant to treatment are advised to use the kinase inhibitor gilteritinib. One of the essential conditions for receiving regulatory approval is increased patient survival rates, which can be achieved through this. Gilderitinib is a safe, mutation-targeted treatment option for individuals with severe, recurrent, or refractory disease. Medication is a complicated pyrazine carboxamide derivative with improved activity, selectivity, and efficacy against FMS-like tyrosine kinase 3 inhibitors3-TKD and FMS-like tyrosine kinase 3 inhibitors3-ITD mutations.

In the region, the North America FMS-like tyrosine kinase 3 inhibitors market holds significant revenue share.

The North America FMS, like the tyrosine kinase 3 inhibitors market, is estimated to hold the biggest share in the market. The demand for FMS-LIKE TYROSINE KINASE 3 INHIBITORS3 inhibitors in North America is expanding rapidly due to expanding government-industry partnerships, approvals of new, novel treatments, and a variety of prospective product approvals. In addition, Asia Pacific is projected to grow rapidly in the global FMS, like the tyrosine kinase 3 inhibitors market. Increasing demands for personalized medicines, an expansion in the percentage of acute myeloid leukemia patients, and increased spending by major pharmaceutical companies on R&D in the domain of FMS-LIKE TYROSINE KINASE 3 INHIBITORS3 inhibitors drug development are a few factors contributing to the market's revenue growth.

Competitive Landscape

Some of the major key players in the FMS-like tyrosine kinase 3 inhibitors market are Astellas Pharma Inc., Novartis AG, Pfizer Inc., Daiichi Sanyo Company, Limited, Cullinan Oncology, Inc., AROG Pharmaceutials, Inc., Aptose Biosciences Inc., FuJFILM Pharmaceuticals U.S.A., Inc., CSPC Pharmaceutical Group Limited, and Allarity Therapeutics, Inc

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global FMS-like Tyrosine Kinase 3 Inhibitors Market Snapshot

Chapter 4. Global FMS-like Tyrosine Kinase 3 Inhibitors Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Drug Type Estimates & Trend Analysis

5.1. by Drug Type & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn) & Volume (no. of units) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Drug Type:

5.2.1. Mideastern

5.2.2. Gilbertian

5.2.3. Sorafenib

Chapter 6. Market Segmentation 2: by Therapies Estimates & Trend Analysis

6.1. by Therapies & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn) & Volume (no. of units) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Therapies:

6.2.1. Type 1 FMS-like tyrosine kinase 3 inhibitors

6.2.2. Type 2 FMS-like tyrosine kinase 3 inhibitors

Chapter 7. FMS-like Tyrosine Kinase 3 Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America FMS-like Tyrosine Kinase 3 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2030

7.1.2. North America FMS-like Tyrosine Kinase 3 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Therapies, 2019-2030

7.1.3. North America FMS-like Tyrosine Kinase 3 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2030

7.2. Europe

7.2.1. Europe FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by Drug Type, 2019-2030

7.2.2. Europe FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by Therapies, 2019-2030

7.2.3. Europe FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by Drug Type, 2019-2030

7.3.2. Asia Pacific FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by Therapies, 2019-2030

7.3.3. Asia Pacific FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by Drug Type, 2019-2030

7.4.2. Latin America FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by Therapies, 2019-2030

7.4.3. Latin America FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by country, 2019-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by Drug Type, 2019-2030

7.5.2. Middle East & Africa FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by Therapies, 2019-2030

7.5.3. Middle East & Africa FMS-like Tyrosine Kinase 3 Inhibitors Market revenue (US$ Million) by country, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Astellas Pharma Inc,

8.2.2. Novartis AG

8.2.3. Pfizer Inc

8.2.4. Daiichi Sanyo Company

8.2.5. Cullinan Oncology, Inc

8.2.6. AROG Pharmaceuticals, Inc.

8.2.7. Aptos Biosciences Inc

8.2.8. Fujifilm Pharmaceuticals

8.2.9. U.S.A., Inc

8.2.10. CSPC Pharmaceutical Group Limited

8.2.11. Alacrity Therapeutics, Inc

8.2.12. Other Prominent Players

By Drug Type Outlook

  • Mideastern
  • Gilbertian
  • Sorafenib

By Therapies Outlook

  • Type 1 FMS-like tyrosine kinase 3 inhibitors
  • Type 2 FMS-like tyrosine kinase 3 inhibitors

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients